@Article{,
AUTHOR = {Jack Barkin},
TITLE = {PSA and the family physician},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {18},
YEAR = {2011},
NUMBER = {Suppl.2},
PAGES = {20--23},
URL = {http://www.techscience.com/CJU/v18nSuppl.2/63032},
ISSN = {1488-5581},
ABSTRACT = {The need for men to undergo screening for prostate cancer 
is controversial. Urologists are concerned about finding 
many men with minimal disease who may not require 
therapy or may be over-treated, while conversely missing 
men with clinically significant prostate cancer that could be 
treated and cured if found at an early enough stage. Most 
men today present to the physician with some symptoms 
attributable to the prostate, and then have a prostatespecific antigen (PSA) test to screen for prostate cancer. 
PSA is still the most effective test to suggest that there may 
be underlying prostate cancer. In addition to measuring 
total PSA, other measures such as PSA density, age-related 
PSA, or PSA velocity can provide further justification 
that a patient should undergo a prostate biopsy to detect 
possible cancer. The American Urological Association has 
developed new guidelines for screening for prostate cancer 
in men who are not at risk. The key is to use one of the PSA 
tools to help diagnose prostate cancer at an early stage and 
then offer aggressive curative therapy, if appropriate, while 
still providing the best quality of life and least chance of 
failure, in the right patient at the right time.},
DOI = {}
}